文献速递泌尿系感染前列腺增生与排尿功能障碍

宁泌泰胶囊治疗慢性前列腺炎/慢性盆腔疼痛综合征的多中心随机双盲安慰剂对照试验

Efficacy and Safety of Ningmitai Capsule in Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial.
PubMed 文献 · Urology · 2021-01-20

该多中心随机双盲安慰剂对照试验纳入120例CP/CPPS男性患者,1:1分配至宁泌泰胶囊或安慰剂治疗4周。结果显示宁泌泰组在2周和4周时NIH-CPSI疼痛评分、总分及生活质量改善均显著优于安慰剂组,应答率更高,且治疗期间未报告不良事件。

要点

  • 宁泌泰胶囊可显著改善CP/CPPS患者疼痛症状和生活质量,最早2周起效。
  • 4周治疗结束时疗效进一步增强,且安全性在本试验中得到确认。
  • 研究为多中心随机双盲安慰剂对照设计,纳入120例患者。

核心结论

  • 宁泌泰胶囊可显著改善CP/CPPS患者的疼痛症状和生活质量,最早2周起效,4周时疗效增强,安全性在本试验中得到确认。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照试验,纳入120例CP/CPPS男性患者,1:1随机分配至宁泌泰胶囊或安慰剂治疗4周,在3个中心开展。

主要发现

  • 治疗2周和4周后,宁泌泰组NIH-CPSI疼痛评分、总分及生活质量的平均下降均显著优于安慰剂组。
  • 宁泌泰组在2周和4周时的应答率均显著高于安慰剂组。
  • 治疗期间未报告不良事件。

关键数值与推荐

  • 主要终点为基线至治疗2周和4周时NIH-CPSI疼痛评分的变化。
  • 次要终点包括NIH-CPSI总分、泌尿症状评分、生活质量及应答率的变化。

临床怎么用

  • 对于CP/CPPS患者,可考虑使用宁泌泰胶囊以改善疼痛症状和生活质量,最早2周可观察到疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To validate the efficacy and safety of Ningmitai capsule (NMT) in the patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). METHODS: We conducted a multicenter, randomized, double-blind, placebo-controlled trial in 120 men with CP/CPPS to evaluate the efficacy and safety of NMT. Participants were randomly assigned (1:1) to NMT or placebo treatment for 4 weeks at 3 centres. The patients were evaluated by the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) at baseline, the end of 2 and 4 weeks of treatment. The primary endpoints were the changes of the NIH-CPSI pain scores from baseline to the end of 2 and 4 weeks of the treatment. The secondary endpoints include the changes of the NIH-CPSI total scores, urinary symptoms scores and the quality of life (QoL) as well as the responder rate. RESULTS: After 2 and 4 weeks of treatment, the mean decreases of the NIH-CPSI pain scores, total scores and QoL in the NMT group were all significantly superior to those in the placebo group. The responder rate was significantly higher in the NMT group than that in the placebo group at both 2 and 4 weeks. No adverse events were reported during the treatment. CONCLUSION: NMT could significantly improve the pain symptoms and QoL in the patients with CP/CPPS as early as in 2 weeks, and the efficacy enhanced at the end of the 4-week treatment. The safety of NMT was confirmed in this trial.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Zhang K, Liu Y, Yang W, et al. Efficacy and Safety of Ningmitai Capsule in Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. Urology. 2021. PMID: 33482135. doi:10.1016/j.urology.2021.01.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。